- Home
- RARE vs AMSC Comparison
RARE vs AMSC Comparison
Compare RARE & AMSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | AMSC |
|---|---|---|
| Founded | 2010 | 1987 |
| Country | United States | United States |
| Employees | N/A | 400 |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2013 | 2012 |
Fundamental Metrics
Financial Performance| Metric | RARE | AMSC |
|---|---|---|
| Price | $26.04 | $56.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 1 |
| Target Price | ★ $59.10 | $52.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 05-05-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.31 | ★ 143.24 |
| EPS | N/A | ★ 3.01 |
| Revenue | ★ $673,000,000.00 | $900,000.00 |
| Revenue This Year | $13.12 | $34.98 |
| Revenue Next Year | $37.80 | $21.38 |
| P/E Ratio | ★ N/A | $18.16 |
| Revenue Growth | ★ 20.13 | N/A |
| 52 Week Low | $18.29 | $20.70 |
| 52 Week High | $40.17 | $70.49 |
Technical Indicators
Market Signals| Indicator | RARE | AMSC |
|---|---|---|
| Relative Strength Index (RSI) | 66.35 | 75.41 |
| Support Level | $23.69 | $54.13 |
| Resistance Level | $29.15 | $64.57 |
| Average True Range (ATR) | 1.08 | 4.15 |
| MACD | 0.05 | 0.88 |
| Stochastic Oscillator | 62.90 | 99.58 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
About AMSC American Superconductor Corporation
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.